Eli Lilly and ImClone - Top 10 deals of 2008

FierceBiotech's top 10 deals of 2008 report featuring Imclone's acquisition of Eli LillyWho: Eli Lilly
With: ImClone System
What: $6.5B buyout

Summary: After rejecting offers from Bristol-Myers Squibb, ImClone accepted Eli Lilly's $6.5 billion offer in October. Lilly outbid BMS more than 10 percent. The deal was announced just weeks after Lilly CEO John Lechleiter said the pharma company would make biotech drugs its preferred choice in the years to come. ImClone is best known for its blockbuster cancer biologic Erbitux, and also has a follow-up drug candidate in its pipeline. In a statement, Lilly said the deal would help it address the issues patent expirations would cause for the company over the next decade.

Eli Lilly and ImClone - Top 10 deals of 2008

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.